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S U M M A R Y
This clinical case reports the emergence of a daptomycin-resistant Staphylococcus aureus isolate during
daptomycin treatment in a patient with right-sided infective endocarditis who had never been treated
with vancomycin.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Staphylococcus aureus is a common pathogen responsible for
bacteremia and endocarditis in developed countries, resulting in
high mortality rates of between 16% and 25%.1 Methicillin-
resistant S. aureus (MRSA) was identiﬁed in more than 25% of
infective endocarditis cases in an observational cohort study.2 In
such cases of MRSA-associated infection, therapeutic options are
limited. The standard antibiotic used for MRSA-associated bacter-
emia – vancomycin – has been associated with suboptimal
outcomes, resulting in the need for new molecules to treat
MRSA-associated bacteremia and endocarditis. Daptomycin, a
semi-synthetic chemical product derived from Streptomyces
roseosporus, is a cyclic lipopeptide with bactericidal activity
against a broad range of Gram-positive bacteria, including MRSA.3
The mechanism of action of daptomycin has not been fully
elucidated. However, it is generally accepted that daptomycin
penetrates the cytoplasmic membrane of Gram-positive bacteria
via a calcium-dependent pathway, resulting in bacterial cell
depolarization, which ultimately induces a rapid bactericidal cell
death.3 In 2006, the Food and Drug Administration approved
daptomycin for the treatment of bloodstream infections (6 mg/kg),* Corresponding author. Tel.: +33 1 45 21 36 32; fax: +33 1 45 21 63 40.
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cin-susceptible S. aureus (including MRSA) and other Gram-
positive bacteria. In addition, daptomycin has been shown to be
well-tolerated at high doses (12 mg/kg/day) and thus may be
considered for the treatment of difﬁcult-to-treat infections.4 The in
vivo acquisition of daptomycin resistance in S. aureus has rarely
been reported, and previous vancomycin exposure is mainly
associated with the emergence of such daptomycin-resistant
strains.3 We report here the emergence of a daptomycin-resistant
S. aureus isolate during daptomycin treatment in a patient with
right-sided infective endocarditis who had never been treated with
vancomycin.
2. Case report
A 55-year-old woman with chronic obstructive pulmonary
disease was hospitalized for an acute respiratory decompensation.
The patient was immediately transferred to the intensive care unit
where mechanical ventilation was established. Three days before her
hospital transfer, the patient had been treated empirically for
pneumonia with amoxicillin–clavulanate (3 g/day) and levoﬂoxacin
(100 mg/day). The amoxicillin–clavulanate treatment was contin-
ued for 7 days. At day 13 post-hospitalization, a bronchoalveolar
lavage was collected when another acute episode of severe septic
pulmonary syndrome occurred. This sample was positive for
Aspergillus and MRSA, leading to a treatment with linezolidses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Scheme of antibiotic treatments and susceptibilities to daptomycin, vancomycin, linezolid, and rifampin of three representative S. aureus strains (S1, S2, and S3)
isolated from blood cultures. Minimal inhibitory concentrations (MICs) were determined using the E-test and broth dilution methods, and interpreted as susceptible (S) or
resistant (R) in accordance with EUCAST guidelines. TEE, transesophageal echocardiogram.
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months. At day 52 post-hospitalization, daptomycin treatment
(7 mg/kg) was started for an MRSA catheter-related bacteremia
associated with hypovolemia (Figure 1). According to the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) breakpoints (http://www.eucast.org), the isolate was
susceptible to daptomycin (MIC = 0.25 mg/l), vancomycin (MIC =
0.75 mg/l), rifampin (MIC = 0.006 mg/l), linezolid (MIC = 0.38 mg/l),
aminoglycosides, chloramphenicol, tetracycline, trimethoprim–sul-
famethoxazole, and fusidic acid, and was resistant to ﬂuoroquino-
lones. On day 60, a transesophageal echocardiogram (TEE) showed a
1.5-cm vegetation on the tricuspid valve. After 8 days of daptomycin
treatment, blood cultures remained positive, with a 3-fold increase in
daptomycin MIC (0.75 mg/l) that was still susceptible. Consequently,
the daptomycin dose was increased to 16 mg/kg/day and associated
with rifampin (1200 mg/day) for possible synergy. Despite
additional 8 days of this therapy, the bacteremia persisted, and an
MRSA isolate recovered from blood culture became resistant to
daptomycin (MIC = 2 mg/l; EUCAST breakpoint value for resistance
>1 mg/l) and rifampin (MIC >32 mg/l), but remained susceptible to
linezolid (MIC = 0.38 mg/l) and vancomycin (MIC = 1.5 mg/l). At
68 days of hospitalization, the antibiotic treatment was switched to a
combination of vancomycin (3 g/day continuous infusion), gentami-
cin (4 mg/kg/day), and linezolid (1200 mg/day). From then, blood
cultures remained negative. Gentamicin and linezolid were discon-
tinued after 5 days and 12 days, respectively (Figure 1). Vancomycin
was continued for 6 weeks, with controls of blood concentrations
showing values remaining between 25 and 35 mg/l. At this stage
(day 113), TEE revealed a slight decrease in the vegetation (1.2 cm).
3. Discussion
The emergence of daptomycin resistance has rarely been
documented in the absence of vancomycin exposure. Fowler
et al. reported an increase in MICs to 2 mg/l or greater in six
patients who were randomly assigned to daptomycin only.5
Contrary to rifampin resistance, no single mutation has been
associated with high-level resistance to daptomycin.3 Instead,
individual mutations in mprF, rpoB, rpoC, and yycG have beenshown to account for two-fold increases in MIC values, and
combinations of mutations are required for higher increases in
MIC values. In addition, daptomycin-resistant S. aureus clinical
isolates have been shown to have mutations in mprF or yycG.3 A
comparison of our daptomycin-susceptible isolate (pre-treat-
ment) and the daptomycin-resistant strain did not detect
mutations in mprF, rpoB, rpoC, and yycG genes, except a single
mutation within the region of the rpoB gene known to confer
resistance to rifampin. The molecular mechanism of this
daptomycin resistance trait remains to be determined.
To the best of our knowledge, this clinical case is the ﬁrst
regarding the de novo development of daptomycin resistance with
clinical failure to cure MRSA during endocarditis therapy, without
previous treatment with vancomycin and without any de novo
mutation in mprF, rpoB, rpoC, or yycG genes.
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